Drugmaker Alkermes put up some astounding growth numbers and its stock rose sharply as a result. Until last quarter that is. The Street doesn't seem concerned though by the blip last quarter. Its stock is up about 27% in the last three months and continues to rise.
The Relative Strength (RS) Rating for Alkermes moved up into a new percentile Monday, as it got a lift from 64 to 76. The upgraded 76% RS Rating shows that Alkermes stock tops 76% of all stocks for price performance this past year.
It's nearing a key benchmark. Market research shows that the best growth stocks often have an 80 or higher RS Rating when they launch their biggest moves, and it's just a few points below that.
Alkermes Profits Surged, Except Last Quarter
Over the past four quarters Alkermes reported 277% earnings growth, then 20%, 155% and an 8% drop last quarter. Its EPS dip last quarter is partly due to a tough comp with the same quarter a year earlier when its earnings soared 255%. Quarterly revenue this past year rose 51%, 42%, 22% and a 35% decrease to $399.1 million last quarter.
Third quarter earnings results are due on or around Oct. 23.
Can You Really Time The Stock Market?
Ireland-based Alkermes develops treatments for cancer and neurodegenerative diseases (conditions that damage and can destroy parts of the nervous system).
Watchlist candidate Alkermes stock is trying to complete a cup without handle with a 32.88 buy point. It traded just above 29 Monday afternoon, up about 0.5% for the day. See if the stock can break out in volume at least 40% above average.
Among Top 20 In Huge Group
Alkermes holds the No. 19 rank among its peers in the 735-stock Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks in the group.
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Please follow James DeTar on X, formerly known as Twitter, @JimDeTar
RELATED:
Get Full Access To IBD Stock Lists And Ratings
Biotech And Pharmaceutical Industry And Stock News
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
